Evidence map›Paper›PMID 42086904›Full record

ArticleEMBO molecular medicine2026

Costimulation loss enhances IL-2-driven Treg generation by PI3K-STAT3 inhibition in CNS autoimmunity.

Kyung-Ho Nam, Gil-Ran Kim, Yu-Rim Kim, Young Nam Kwon, Sung-Min Kim, Je-Min Choi

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kyung-Ho Nam *Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.ORCID 0000-0003-3951-663X
Gil-Ran Kim *Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.ORCID 0000-0003-1629-6945
Yu-Rim KimDepartment of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.
Young Nam KwonDepartment of Neurology, Kangbuk Samsung Hospital, Seoul, Republic of Korea.ORCID 0000-0002-3588-274X
Sung-Min KimDepartment of Neurology, Seoul National University, College of Medicine, Seoul, Republic of Korea.ORCID 0000-0003-2425-6388
Je-Min ChoiDepartment of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea. jeminchoi@hanyang.ac.kr.ORCID 0000-0002-9482-710X

Funding

Korea Basic Science Institute (KBSI) 2023R1A6C101A009National Research Foundation of Korea (NRF) RS-2023-00210407National Research Foundation of Korea (NRF) RS-2024-00334289National Research Foundation of Korea (NRF) RS-2024-00439160National Research Foundation of Korea (NRF) RS-2025-02232977
6 · The paper itself

Abstract

Costimulation blockade with CTLA-4 Ig (Abatacept) is a widely used strategy to suppress autoreactive T cells; however, its efficacy is often self-limiting due to concurrent depletion of regulatory T cells (Tregs), which depend on CD28 signaling for homeostasis. Here, we demonstrate that costimulation blockade paradoxically potentiates IL-2-driven Treg generation by selectively reprogramming intracellular cytokine signaling. We identified that IL-2 activates STAT3 only in the presence of TCR stimulation, as this pathway requires CD28-mediated PI3K-AKT signaling, which is abrogated by costimulation blockade. Consequently, CTLA-4 Ig uncouples STAT3 activation from IL-2 signaling while sparing STAT5, thereby enhancing TGF-β/Smad2/3 signaling to induce Foxp3 expression. This dual action-sustained STAT5 activation and increased Smad2/3 signaling-promoted robust Treg generation that ameliorated experimental autoimmune encephalomyelitis (EAE). Furthermore, we confirmed that this synergistic effect is conserved in human T cells from patients with multiple sclerosis (MS) upon CTLA-4 Ig and IL-2 cotreatment. Our findings suggest a strategy to expand the utility of CTLA-4 Ig therapy, providing a mechanistic rationale for combining costimulation blockade with IL-2 to restore immune tolerance in CNS autoimmunity.

Indexed as

AutoimmunityCentral Nervous SystemInterleukin-2Phosphatidylinositol 3-KinasesSTAT3 Transcription FactorT-Lymphocytes, RegulatoryAnimalsCD28 AntigensCTLA-4 AntigenEncephalomyelitis, Autoimmune, ExperimentalFemaleForkhead Transcription FactorsHumansMiceMice, Inbred C57BLMultiple SclerosisCD28 AntigensCTLA-4 AntigenForkhead Transcription FactorsInterleukin-2Phosphatidylinositol 3-KinasesSTAT3 Transcription Factor

Identifiers

PMID42086904
PMCPMC13269791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.